tiprankstipranks
Trending News
More News >
Sunshine Biopharma (SBFM)
NASDAQ:SBFM
US Market

Sunshine Biopharma (SBFM) AI Stock Analysis

Compare
407 Followers

Top Page

SB

Sunshine Biopharma

(NASDAQ:SBFM)

Rating:40Underperform
Price Target:
Sunshine Biopharma's stock score is primarily impacted by financial performance challenges, including significant yet unprofitable revenue growth and negative cash flows. Technical analysis indicators suggest bearish momentum, further influencing the negative outlook. Valuation concerns, such as a negative P/E ratio and lack of dividend yield, also weigh on the score. The company needs to address operational inefficiencies and improve profitability to enhance its stock performance.

Sunshine Biopharma (SBFM) vs. SPDR S&P 500 ETF (SPY)

Sunshine Biopharma Business Overview & Revenue Model

Company DescriptionSunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
How the Company Makes MoneySunshine Biopharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company earns money by advancing its drug candidates through clinical trials and ultimately receiving regulatory approval to market these drugs. Upon approval, it can generate revenue from sales of its proprietary drugs. Additionally, Sunshine Biopharma may enter into strategic partnerships or licensing agreements with other pharmaceutical companies, providing opportunities for upfront payments, milestone payments, and royalties based on product sales. These collaborations can significantly contribute to the company's earnings by leveraging the partner's distribution networks and expertise in specific markets.

Sunshine Biopharma Financial Statement Overview

Summary
Sunshine Biopharma demonstrates significant revenue growth, indicating market expansion. However, persistent profitability challenges, negative net income, and cash flow issues highlight the need for strategic improvements in cost management and operational efficiency. The balance sheet is stable, but the company must enhance its cash flow and achieve profitability to improve financial health and shareholder value.
Income Statement
45
Neutral
Sunshine Biopharma has shown substantial revenue growth over the years, with a significant increase from $21,121 in 2019 to $34,874,283 in 2024. However, the company remains unprofitable, as indicated by negative EBIT, EBITDA, and net income figures across all years, which highlights ongoing operational challenges and cost management issues. The gross profit margin has improved, yet net profit margins remain negative, reflecting a need for better cost control and efficiency to reach profitability.
Balance Sheet
35
Negative
The balance sheet reveals a strong equity position with positive stockholders' equity in recent years, indicating some financial stability. However, the company has experienced fluctuating total assets and liabilities, and a history of negative equity in earlier years. The absence of debt in the latest period is a positive, yet the company's return on equity remains negative, which reflects ongoing profitability issues impacting shareholder value.
Cash Flow
40
Negative
Sunshine Biopharma's cash flow statement highlights a consistent struggle with negative operating and free cash flows, pointing to challenges in generating cash from its operations. Despite this, the company has managed to secure financing, as seen in positive financing cash flows, which have supported its liquidity. Improvements in free cash flow growth are necessary to ensure long-term sustainability.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
34.87M24.09M4.35M228.43K71.41K
Gross Profit
10.67M8.34M1.70M110.60K45.56K
EBIT
-5.81M-4.79M-8.67M-2.44M-576.87K
EBITDA
-5.15M-3.82M-26.45M-12.09M-2.60M
Net Income Common Stockholders
-5.13M-4.51M-26.74M-12.77M-897.68K
Balance SheetCash, Cash Equivalents and Short-Term Investments
9.69M16.29M21.83M2.05M989.89K
Total Assets
30.56M27.35M29.24M2.20M1.05M
Total Debt
952.48K657.71K4.27M1.90M1.91M
Net Debt
-8.73M-15.63M-17.55M-145.17K923.23K
Total Liabilities
7.06M6.14M7.62M1.99M2.00M
Stockholders Equity
23.50M21.21M21.63M211.66K-954.84K
Cash FlowFree Cash Flow
-14.85M-9.56M-5.55M-1.83M-658.49K
Operating Cash Flow
-12.53M-8.78M-5.25M-1.83M-657.30K
Investing Cash Flow
-2.32M-656.15K-14.62M0.00-1.19K
Financing Cash Flow
9.29M3.43M39.47M2.90M1.61M

Sunshine Biopharma Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.43
Price Trends
50DMA
1.57
Negative
100DMA
2.08
Negative
200DMA
2.49
Negative
Market Momentum
MACD
-0.02
Negative
RSI
49.51
Neutral
STOCH
55.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Neutral. The current price of 1.43 is above the 20-day moving average (MA) of 1.37, below the 50-day MA of 1.57, and below the 200-day MA of 2.49, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 49.51 is Neutral, neither overbought nor oversold. The STOCH value of 55.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SBFM.

Sunshine Biopharma Risk Analysis

Sunshine Biopharma disclosed 32 risk factors in its most recent earnings report. Sunshine Biopharma reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If we are unable to continue to meet the listing requirements of Nasdaq, our common stock will be delisted Q4, 2023

Sunshine Biopharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$5.19B3.33-45.04%2.83%17.58%-0.66%
49
Neutral
$5.14M-64.83%13.51%78.93%
49
Neutral
$6.88M-59.14%-33.10%71.37%
46
Neutral
$5.70M-108.77%97.84%82.99%
40
Underperform
$6.52M-21.17%35.51%95.44%
38
Underperform
$4.22M1155.92%
34
Underperform
$3.82M-129.08%9.41%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SBFM
Sunshine Biopharma
1.44
-11.24
-88.64%
CPHI
China Pharma Holdings
2.00
-1.00
-33.33%
SNOA
Sonoma Pharmaceuticals
3.22
-1.98
-38.08%
EVOK
Evoke Pharma
3.52
-1.87
-34.69%
RDHL
RedHill Biopharma
1.80
-9.58
-84.18%
PRFX
PainReform
1.95
-14.85
-88.39%

Sunshine Biopharma Corporate Events

Executive/Board Changes
Sunshine Biopharma Strengthens Leadership with New Executive Agreements
Positive
Oct 23, 2024

Sunshine Biopharma Inc. has solidified its leadership team with new employment agreements for its top executives, effective January 1, 2024. Dr. Steve N. Slilaty, CEO, Camille Sebaaly, CFO, and Dr. Abderrazzak Merzouki, COO, will receive annual salary hikes tied to inflation or a minimum increase, whichever is higher. In case of termination without cause, substantial severance packages are promised, ensuring stability and confidence in the company’s future growth strategies.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.